LIMINATUS PHARMA, INC. Prepaid Expense and Other Assets, Current
LIMINATUS PHARMA, INC. (LIMN) had Prepaid Expense and Other Assets, Current of $375.37 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-14
- 2026-06-30: Prepaid Expense and Other Assets, Current $375.37K.
- 2026-03-31: Prepaid Expense and Other Assets, Current $870.87K.
- 2025-12-31: Prepaid Expense and Other Assets, Current $162.92K.
- 2025-09-30: Prepaid Expense and Other Assets, Current $478.87K.
| Period end | Prepaid Expense and Other Assets, Current |
|---|---|
| 2026-06-30 | $375.37K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $870.87K S-1 · filed 2026-06-24 |
| 2025-12-31 | $162.92K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $478.87K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $444.09K 10-Q · filed 2025-10-06 |
| 2024-12-31 | $155.50K S-1 · filed 2026-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |